Healthy volunteers to test experimental lung disease drug
NCT ID NCT07493031
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug, HW252001, in 98 healthy adults aged 18 to 55. The goal is to check the drug's safety and how the body processes it, not to treat any disease. Participants will receive either the drug or a placebo, and researchers will monitor for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breath test predict lung scarring? new study seeks answers
- New inhaled drug for lung disease tested in healthy people first
- New hope for lung scarring: HSK44459 enters final trial phase
- New drug for lung scarring takes first step in healthy volunteers
- Simple questionnaire could bring palliative care home for lung disease patients
- New drug MN-001 tested for scarred lungs in tiny trial